Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
Dermata set August 25, 2026, as the launch date for its first commercial product, the Tome Foundational Treatment, marking its transition to a direct-to-consumer skincare model. Financial results for the second quarter showed cash decreased to $4.4 million from $7.5 million at year-end, with operations consuming $4.9 million over the past six months.
Key figures
- Net loss
- 2967000
- Cash runway
- Q4 2026
- Rd expenses
- 213000
- Atm proceeds
- 1900000
- Cash balance
- 4413000
- Sga expenses
- 2801000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.